


Minor change in the structure major change in the mass spectrum in the example of an N-toluene-pyrrolidine derivative

## József Pánczél

Disposition, Safety&Animal Research, Drug Disposition sanofi-aventis/Chinoin H-1045, Tó utca 1-5. Budapest

## **Budapest**

- SAR is a N-toluene-pyrrolidine derivative (partly shown in this poster) under development at sanofi-aventis
- \* The masses of fragments in MS2 correspond to separate moieties of SAR
- Most of the changes in the parent drug metabolism result in very similar mass spectra
- MS2 and further MSn spectra can indicate the parts metabolized, but cannot help in finding the exact structure of either the unchanged drug or most of the metabolites




## Evidences for being metabolites:

- Radioactivity
- \*12C/14C isotope pattern (in vitro metabolism study with 14C labelled material)
- \*Accurate mass of molecular ions and their mass spectrometric fragments



Two different metabolites with this MS2 spectra






Conclusion (Benefits of this finding)

- The structures of two of most important metabolites were elucidated
- \*It is likely that the two metabolites differ only in the position of the double bound in the dehydro-pyrrolidine ring ⇒ to be proven by standards
- #10 other metabolites of all the 59 metabolites of SAR have similar MS fragmentation pattern i.e. two-electron oxidation in the pyrrolidine ring is a major metabolic pathway
- \*Based on the above findings and using other important MSn fragments the exact or almost the exact structure of some important metabolites (most of them formed by multiple and complex metabolic reactions) of SAR could be elucidated

The unique MS<sup>3</sup> fragmentation of the 311 MS<sup>2</sup> fragment of the metabolite appeared the same as the MS2 fragmentation of the impurity of SAR





Because health matters